Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
Journal: The New England journal of medicine
Published: July 29, 2026
Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.
Journal: Lancet (London, England)
Published: July 07, 2026
Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._.
Journal: Communications medicine
Published: July 18, 2025
The Effects of Cobicistat and Voriconazole on the Safety, Pharmacokinetics, and Pharmacodynamics of the TLR7 Agonist Vesatolimod in People with HIV.
Journal: Infectious diseases and therapy
Published: June 13, 2025
Combination immunotherapy induces post-intervention control of HIV.
Journal: Research square
Published: April 01, 2025
Correlates of HIV-1 control after combination immunotherapy.
Journal: Nature
Published: March 02, 2025
Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial.
Journal: Nature communications
Published: October 31, 2024
Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies.
Journal: Nature communications
Published: October 29, 2024
Differential shaping of T cell responses elicited by heterologous ChAd68/self-amplifying mRNA SIV vaccine in macaques in combination with αCTLA4, αPD-1, or FLT3R agonist.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: August 14, 2024
A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod.
Journal: Infectious diseases and therapy
Published: July 12, 2024
Early Viral Dynamics Predict Human Immunodeficiency Virus Posttreatment Control After Analytic Treatment Interruption.
Journal: The Journal of infectious diseases
Published: July 02, 2024
Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimod.
Journal: Frontiers in immunology
Published: March 22, 2024
Last Updated: 09/26/2026